Skip to main content
Premium Trial:

Request an Annual Quote

Castle Biosciences Closes $20M Credit Facility

NEW YORK (GenomeWeb) – Oxford Finance and Silicon Valley Bank said today that they have closed a $20 million credit facility with Castle Biosciences.

The credit facility comprises a $15 million senior secured term loan and a $5 million line of credit. Castle Bio, which is based in Friendswood, Texas, will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.

Specifically, Castle Bio offers DecisionDx-Melanoma for cutaneous melanoma, DecisionDx-UM for uveal melanoma, and DecisionDx-PRAME for a rare and aggressive eye cancer. DecisionDx-Melanoma, for example, uses RT-PCR to analyze the expression of 31 genes within melanomas, and can more accurately predict distant metastases in Stages I and II patients than can current staging factors, according to the company.

The company offers all of its tests out of its CLIA-certified, CAP-accredited laboratory in Phoenix, Arizona.

"Castle Biosciences is focused on delivering high-value tests to improve cancer treatment. This expanded capital facility will be used to accelerate growth of our cutaneous melanoma test, DecisionDx-Melanoma, and support our near-term pipeline," Castle Bio  President and CEO Derek Maetzold said in a statement.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.